GAS7 has been shown to be directly regulated by P53 and is part of a critical mechanism that mediates breast cancer metastasis [74]; NRG1 fusions were identified as drivers for lung adenocarcinoma [79]; And the involvement of PRDM16 in leukemia [80], ARID1B in ovarian cancer [81], and AFF1 in leukemia [82] has also been reported; It has been demonstrated that a GAS7-mediated pathway suppressed proliferation of HCC cells following treatment with oxaliplatin, an alkylating anti-neoplastic agent, and the inhibition of GAS7 negated the beneficial effects of the drug [83]. Here, PRDM16 is linked to ovarian cancer.